ScholarIQanswers from OpenAlex & ORCID
Tanja Fehm
ResearcherPublications, citations & collaboration network
Tanja Fehm is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Tanja Fehm have?
ScholarIQindexed works
Tanja Fehm has 1,955 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Tanja Fehm have?
ScholarIQcitation count
Tanja Fehm has 35,432 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Tanja Fehm?
ScholarIQh-index
Tanja Fehm has an h-index of 85 in OpenAlex.
What is the i10-index of Tanja Fehm?
ScholarIQi10-index
Tanja Fehm has an i10-index of 464 in OpenAlex.
What is the ORCID of Tanja Fehm?
ScholarIQorcid
The ORCID for Tanja Fehm is on the source record.
What is the OpenAlex record for Tanja Fehm?
ScholarIQopenalex
The OpenAlex for Tanja Fehm is on the source record.
What are the most-cited papers on Tanja Fehm?
ScholarIQmost cited works
Circulating Tumor Cells in Patients with Breast Cancer Dormancy
Songdong Meng, Debasish Tripathy, Eugene P. Frenkel, Sanjay Shete, Elizabeth Z. Naftalis, James F. Huth, Peter D. Beitsch, Marilyn Leitch, Susan Hoover, David Euhus, Barbara Haley, Larry E. Morrison, Timothy P. Fleming, Dorothee Herlyn, Leon W.M.M. Terstappen, Tanja Fehm, Thomas F. Tucker, Nancy Lane, Jianqiang Wang, Jonathan W. Uhr
<i>HER-2</i> gene amplification can be acquired as breast cancer progresses
Songdong Meng, Debasish Tripathy, Sanjay Shete, Raheela Ashfaq, Barbara Haley, Steve Perkins, Peter D. Beitsch, Amanullah Khan, David Euhus, Cynthia Osborne, Eugene P. Frenkel, Susan Hoover, Marilyn Leitch, Edward Clifford, Ellen S. Vitetta, Larry E. Morrison, Dorothee Herlyn, Leon W.M.M. Terstappen, Timothy P. Fleming, Tanja Fehm, Thomas F. Tucker, Nancy Lane, Jianqiang Wang, Jonathan W. Uhr
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Wolfgang Janni, Brigitte Rack, Leon W.M.M. Terstappen, Jean‐Yves Pierga, Florin‐Andrei Taran, Tanja Fehm, Carolyn Hall, Marco R. de Groot, François‐Clément Bidard, Thomas W. P. Friedl, Peter A. Fasching, Sara Y. Brucker, Klaus Pantel, Anthony Lucci
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Fabrice André, Yeon Hee Park, Sung‐Bae Kim, Toshimi Takano, Seock‐Ah Im, Giuliano Borges, João Paulo da Silveira Nogueira Lima, Sercan Aksoy, Joaquín Gavilá Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruíz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, François P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Wu Cai, Changan Chu, Anton Egorov, Ian E. Krop
Borderline tumours of the ovary: A cohort study of the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group
Andreas du Bois, Nina Ewald-Riegler, Nikolaus de Gregorio, Alexander Reuß, Sven� Mahner, Christina Fotopoulou, Friedrich Kommoss, Barbara Schmalfeldt, Felix Hilpert, Tanja Fehm, Alexander Burges, Werner Meier, Peter Hillemanns, Lars Hanker, Annette Hasenburg, Hans‐Georg Strauß, Martin Hellriegel, Pauline Wimberger, Mignon-Denise Keyver-Paik, Klaus Baumann, Ulrich Canzler, K. Wollschlaeger, Dirk Michael Forner, Jacobus Pfisterer, W. Schröder, Karsten Münstedt, Barbara Richter, Stefan Kommoss, Steffen Hauptmann